Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone in social phobia

F R Schneier1, J B Saoud, R Campeas

  • 1Anxiety Disorders Clinic, New York State Psychiatric Institute, NY 10032.

Journal of Clinical Psychopharmacology
|August 1, 1993
PubMed
Summary

Buspirone shows modest effectiveness for social phobia treatment. High doses (≥45 mg/day) yielded better results, with 67% of patients improving significantly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing first line treatments for adults with OCD.

Comprehensive psychiatry·2022
Same author

Obsessive-compulsive disorder during the COVID-19 pandemic.

Journal of psychiatric research·2022
Same author

Potential of cannabinoids as treatments for autism spectrum disorders.

Journal of psychiatric research·2021
Same author

The Future of Obsessive-Compulsive Spectrum Disorders: A Research Perspective.

Current topics in behavioral neurosciences·2021
Same author

How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology.

Comprehensive psychiatry·2020
Same author

Rapid atrial fibrillation, rapid cardioversion, rapid return home.

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias·2019

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Buspirone is an anxiolytic effective for generalized anxiety disorder.
  • Its efficacy in phobic disorders, particularly social phobia, is not well-established.

Purpose of the Study:

  • To evaluate the efficacy of buspirone in treating social phobia.
  • To assess buspirone's effects on social anxiety and avoidance behaviors.

Main Methods:

  • A 12-week open-label trial involving 21 patients with social phobia.
  • Patients received buspirone after a 1-week placebo washout period.
  • Outcome measures included the Clinical Global Impression Scale, social anxiety, and avoidance measures.

Main Results:

Related Experiment Videos

  • 47% of patients (8/17) showed significant improvement in social phobia symptoms.
  • Higher doses (≥45 mg/day) were associated with greater improvement (67% improved).
  • Significant reductions in social anxiety and avoidance were observed; generalized anxiety and depression did not change.

    • Conclusions:

    • Buspirone may offer modest therapeutic benefits for social phobia.
    • Higher doses might be more effective.
    • Further placebo-controlled trials are necessary to confirm these findings.